

## Dan Kidle, Principal

Dan Kidle joined Arboretum Ventures in 2011 as an Analyst. In his current role as Principal, Dan focuses on supporting Arboretum's portfolio companies and leading new investments across the firm's sectors of interest, with particular emphasis on life science tools. Since joining Arboretum, Dan has undertaken significant due diligence responsibilities to support more than a dozen of Arboretum's new and follow-on investments, including Ebb Therapeutics, NeuMoDx, IntelliCyt, Rethink, Cardiac Dimensions, Strata Oncology, SI-BONE, and Swift Biosciences. Dan's portfolio company involvement has included serving on the board of directors for life science tools company IntelliCyt, until its \$90 million acquisition by Sartorius in 2016. Dan currently serves on the Board of Directors for Swift Biosciences and as a board observer for NeuMoDx and Strata Oncology.

Outside of Arboretum, Dan serves on the Oversight Committee for Wayne State University's M-TRAC program and on the Investment Advisory Board for the Monroe-Brown Biomedical Seed Fund at the University of Michigan.

Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company's U.S. sales and marketing operations. Dan earned his BBA and MBA from the Ross School of Business at the University of Michigan.